Potential Therapeutic Action of Adiponectin in Duchenne Muscular Dystrophy

• Published in: The American journal of pathology Vol. 187; no. 7; pp. 1577 - 1585
• Main Authors: Abou-Samra, Michel, Boursereau, Raphaël, Lecompte, Sophie, Noel, Laurence, Brichard, Sonia M
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2017
• Subjects: Adiponectin - administration & dosage; Adiponectin - deficiency; Adiponectin - genetics; Adiponectin - metabolism; Animals; Disease Models, Animal; Humans; Inflammation - immunology; Inflammation - prevention & control; Male; Metabolism, Inborn Errors - drug therapy; Metabolism, Inborn Errors - genetics; Metabolism, Inborn Errors - physiopathology; Mice; Mice, Inbred mdx; Mice, Knockout; Muscle Development - drug effects; Muscle, Skeletal - drug effects; Muscle, Skeletal - physiopathology; Muscular Dystrophy, Duchenne - drug therapy; Muscular Dystrophy, Duchenne - genetics; Muscular Dystrophy, Duchenne - physiopathology; NF-kappa B - immunology; Pathology
• ISSN: 0002-9440; 1525-2191
• DOI: 10.1016/j.ajpath.2017.02.018

Adiponectin (ApN) is a hormone that exhibits anti-inflammatory effects on skeletal muscle exposed to acute and chronic inflammation. We have previously tested the implication of ApN in Duchenne muscular dystrophy (DMD) using mdx mice, a model of DMD, and by generating transgenic mdx mice overexpressing ApN. We showed that ApN can act as a preventive agent and delay disease progression by reducing muscle inflammation/injury and improving force/myogenesis. Herein, we took an opposite approach and crossed mdx mice with ApN knockout mice, to obtain mdx mice with ApN depletion. The aims were to test whether ApN deficiency could worsen the mdx phenotype and whether ApN supplementation can reverse several muscle abnormalities once the disease is settled. mdx-knocout mice exhibited lower muscle force/endurance as well as increased muscle damage when compared to regular mdx mice. Local administration of the ApN gene significantly reduced the expression of several oxidative stress/inflammatory markers and increased the expression of myogenic markers in the skeletal muscle. Finally, the presence of ApN markedly reduced the activity of NF-κB, a key player in muscle inflammation and myogenesis. ApN proves to be a powerful protector of the skeletal muscle capable of reversing the disease progression, thus making it a potential therapeutic agent for DMD.